NCT07570719 Community-based Screening for Alzheimer's Disease
| NCT ID | NCT07570719 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kuang XiaoJun |
| Condition | Alzheimer's Disease(AD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2026-05-01 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective, multicenter, observational cohort study is to evaluate the screening performance of blood-based biomarkers for Alzheimer's disease (AD) in a real-world community screening setting, and to establish the population baseline levels and reference intervals of these biomarkers in Chinese older adults. The main questions it aims to answer is: What is the clinical screening value of blood biomarkers (phosphorylated tau 217 to amyloid β 42 ratio \[pTau217/Aβ42\] and glial fibrillary acidic protein \[GFAP\]) for AD among community-dwelling older adults? Eligible study participants will be randomly enrolled from community-dwelling older adults undergoing routine physical examinations and outpatient clinic attendees. All enrolled participants will undergo AD screening via blood biomarker testing. Participants with positive blood biomarker results (defined as abnormal pTau217/Aβ42 ratio and/or GFAP levels) will further complete a full battery of cognitive scale assessments, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Activities of Daily Living (ADL) scale, and 17-item Hamilton Depression Rating Scale (HAMD-17). In addition, 15% of participants with negative blood biomarker results, selected via random sampling, will also complete the same cognitive scale assessments.
Eligibility Criteria
Inclusion Criteria: * Aged 60-80 years * Capable of normal communication and able to complete the questionnaire Exclusion Criteria: * Severe mental disorders * Severe visual, auditory, comprehension or mobility impairments * Current participation in other health intervention clinical studies * Severe renal insufficiency, heart failure, cerebrovascular disease, anemia, hyperthyroidism, hypothyroidism * Multiple cerebral infarctions, severe white matter hyperintensities, history of cerebral hemorrhage, current anticoagulant use, MRI abnormalities (cortical iron deposition, cerebral contusion) * Unable to comply with study procedures with no legal guardian
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07570719 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Alzheimer's Disease(AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07570719 currently recruiting?
Yes, NCT07570719 is actively recruiting participants. Contact the research team at xj_kuang@126.com for enrollment information.
Where is the NCT07570719 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China, Shanghai, China, Shanghai, China.
Who is sponsoring the NCT07570719 clinical trial?
NCT07570719 is sponsored by Kuang XiaoJun. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.